Centella Asiatica & Wound Healing Botanicals: Madecassoside vs Asiaticoside Data

Overview #

If your brand is building a barrier-repair or sensitive-skin line, the first question we ask is not “which extract do you want?” — it’s “what do you actually need the molecule to do?” Centella asiatica is not one ingredient. It’s a family of triterpene compounds with meaningfully different bioactivities, stabilities, and regulatory footprints. Madecassoside and asiaticoside are the two most commercially relevant, and choosing between them — or combining them — changes your formulation strategy, your stability protocol, and your on-pack claims. We’ve run enough projects with both to have strong opinions about where each one belongs.

The Molecules Behind the Plant: What You’re Actually Buying #

Raw Centella extract is a mixture. Depending on the supplier and extraction method, you’re looking at four primary triterpene compounds: madecassoside, asiaticoside, madecassic acid, and asiatic acid. The glycosides (madecassoside and asiaticoside) are water-soluble and more stable in aqueous systems. The aglycones (madecassic acid and asiatic acid) are lipophilic and behave very differently in emulsion systems.

When a brand brief says “we want Centella,” we immediately ask for the spec sheet. A “10% Centella extract” from one supplier might contain 40% total triterpenes by HPLC, while another supplier’s “10% extract” contains 8%. We’ve seen both on the same project. The numbers on the CoA matter more than the extract percentage on the label.

Madecassoside is the compound with the strongest wound-healing and anti-inflammatory data. It inhibits pro-inflammatory cytokines — specifically, we’ve seen consistent suppression of IL-1β and TNF-α in keratinocyte models at concentrations as low as 0.1%. Asiaticoside’s primary mechanism is collagen synthesis stimulation via TGF-β1 upregulation, which makes it more relevant for anti-aging and scar remodeling briefs than for acute barrier repair.

The distinction matters commercially. A brand positioning around “calming redness” needs madecassoside as the lead compound. A brand positioning around “firming and scar fading” should be leading with asiaticoside or the aglycone fraction. We almost always push back when a brief conflates these two use cases.

Comparative Data: Grades, Purity, and What They Actually Deliver #

This is where most brand partners need the most education. The market offers everything from crude Centella powder to 98%+ isolated madecassoside, and the performance gap between them is not linear — it’s categorical.

TECA deserves a separate note. It’s a specific standardized blend — 40% asiaticoside, 29% asiatic acid, 29% madecassic acid, 2% madecassoside — originally developed for pharmaceutical wound care. When brand partners ask for it, we have to be direct: it’s effective, but you’re locked into one supplier’s supply chain, and the cost per kilogram is roughly 4–6× a comparable standardized extract. For most indie brands at MOQ 500–1000 units, that math doesn’t work.

For regulatory context, all of these compounds fall under cosmetic ingredient status in the EU under EU Cosmetics Regulation 1223/2009, with no current concentration restrictions. In the US, FDA Cosmetics Guidelines treat them as cosmetic actives with no OTC drug classification — provided claims stay on the cosmetic side of the line. China’s NMPA Cosmetic Regulation lists Centella asiatica extract as a permitted cosmetic raw material, but isolated madecassoside at high purity may require additional documentation under the new 2021 ingredient registration framework. We flag this for every China-market brief.

Clinical Evidence: What the Data Actually Shows #

The head-to-head clinical data between madecassoside and asiaticoside is thinner than most ingredient suppliers will admit. Most published studies use TECA or standardized extract blends, not isolated compounds. We’re still not fully convinced the isolated compound data is strong enough to make clean head-to-head efficacy claims without more independent replication.

That said, the most relevant study for barrier-repair positioning is a double-blind, randomized controlled trial (n=40, 8 weeks) evaluating a 0.1% madecassoside cream versus vehicle control in subjects with mild atopic dermatitis. The madecassoside group showed a 34% reduction in TEWL (transepidermal water loss) versus 11% in the vehicle group, and a 28% improvement in IGA (Investigator Global Assessment) score. Erythema scores dropped by 41% in the active group. These are meaningful numbers for a cosmetic claim — “supports barrier function” and “visibly reduces redness” are both defensible from this data.

For asiaticoside, the collagen synthesis data is more compelling in vitro than in vivo. Fibroblast studies consistently show 20–35% upregulation of collagen type I at 0.2–0.5% concentration. The clinical translation is less clean. In our own stability and efficacy tracking across client projects, we’ve observed that asiaticoside-led formulas tend to show visible results in consumer perception studies at 10–12 weeks, not 4–6 weeks. Brands that want fast visible results should know this upfront.

For broader context on stability testing protocols we apply to these actives, ICH Stability Guidelines inform our accelerated stability design — 40°C/75% RH for 12 weeks minimum before we sign off on a formula.

See also our technical documentation on barrier repair and sensitive skin formulation for how we integrate Centella actives into full formula systems.

Where Most Brands Get This Wrong #

Honestly, the most common mistake is treating Centella as a marketing ingredient rather than a functional one. A brand will request “Centella extract” at 1% because they’ve seen it on competitor labels, without specifying which fraction or what the extract is standardized to. We end up with a formula that has Centella on the INCI list but essentially no meaningful active load.

The second mistake is pH. Madecassoside is stable across pH 4.5–7.0, which is workable. But asiaticoside starts showing hydrolysis above pH 6.5 in our accelerated stability data — we see the glycoside cleaving to the aglycone form, which changes the bioavailability profile and can cause unexpected color shift in the formula. Most brands don’t realize this until we show them the HPLC overlay at week 8.

The third mistake — and this is where projects go sideways — is combining high-purity Centella actives with vitamin C systems. At pH 3.0–3.5 (typical for L-ascorbic acid formulas), madecassoside degrades measurably within 4 weeks at 40°C. We’ve had to rebuild two client formulas because of this. If a brand wants both actives, we route them into separate SKUs or use a stabilized vitamin C derivative that allows a higher working pH. Our vitamin C and antioxidant systems documentation covers the pH compatibility matrix in detail.

One pilot batch failure worth sharing: a client requested 0.3% isolated madecassoside in a water-in-silicone emulsion. Worked perfectly at 500g lab scale. At 180kg production, we saw phase separation at week 6 of PCT. The root cause was the madecassoside supplier’s excipient system — the lab-scale batch used a different lot with a slightly different carrier blend that had better emulsion compatibility. We now require full lot-matched stability data from suppliers before scaling. It’s not a perfect solution, but it’s caught three similar issues since.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions. A Korean-market “cica” product has different consumer expectations than a EU clinical skincare line, and the formulation brief should reflect that.

For barrier-repair and sensitive-skin positioning, we typically lead with madecassoside at 0.1–0.3% as the primary active, supported by a ceramide-fatty acid system and a humectant base. The Centella does the anti-inflammatory work; the lipid system does the barrier reconstruction. Trying to make Centella carry both functions usually means you’re underdelivering on one.

For anti-aging and scar-fading positioning, we build around asiaticoside at 0.2–0.4% with a peptide co-active — typically a TGF-β mimetic peptide to amplify the collagen synthesis pathway. The combination is more effective than either alone in our internal testing, though we’re careful about how we frame that claim externally.

Texture matters more than most brands expect. High-purity madecassoside is a white powder that disperses cleanly in water phase. Crude extracts can introduce color (yellow-brown) and odor that require masking. If your brand aesthetic is “clean, minimal, fragrance-free,” crude extract creates problems that isolated actives don’t. Budget accordingly — isolated madecassoside runs roughly 2.5–3× the cost of a standardized extract on a per-active-unit basis.

For brands entering the China market, build in 8–12 weeks for ingredient documentation review under the current NMPA framework. We’ve seen this timeline catch brands off guard at launch.

Frequently Asked Questions #

Q: We want to call it a “cica cream” — does it matter which Centella ingredient we use?
“Cica” is a marketing term, not a regulated one, so technically any Centella-derived ingredient qualifies. But if you’re making barrier-repair claims, you want madecassoside as the lead active at minimum 0.1% — that’s the compound with the strongest anti-inflammatory data. A crude extract at 0.5% with no standardization spec is not the same thing, and we’ll tell you that upfront.

Q: Can we combine madecassoside and niacinamide in the same formula?
Yes, and it’s actually a strong combination for sensitive-skin positioning. Niacinamide at 4–5% pairs well with madecassoside at 0.1–0.2% — compatible pH range (5.0–6.5), complementary mechanisms (barrier + anti-inflammatory), and no stability conflicts we’ve observed across 12-week PCT. One of our more reliable combinations.

Q: What’s the minimum effective concentration for madecassoside?
In our formulation experience, 0.05% shows measurable anti-inflammatory activity in cell models, but for consumer-perceivable results in a leave-on product, we recommend 0.1% as the floor. Below that, you’re essentially paying for label presence. Some suppliers will tell you 0.01% is active — we’re skeptical of that claim at the cosmetic application level.

Q: Is TECA worth the premium for a mass-market product?
Rarely. TECA’s advantage is its specific standardized ratio, which has pharmaceutical heritage and strong clinical backing. For a mass-market SKU at MOQ 5,000+ units, the cost premium — typically 4–6× versus a standardized extract — is hard to justify unless your brand story is explicitly built around that clinical heritage. Most brands are better served by a well-specified standardized extract with HPLC certification.

Q: How do we handle Centella actives for a China NMPA registration?
Centella asiatica extract is on the permitted ingredient list, so standard extracts are straightforward. Isolated high-purity compounds (≥90% madecassoside or asiaticoside) may be classified as new cosmetic ingredients under the 2021 regulations, which triggers a separate registration pathway — budget 6–12 months and additional dossier preparation. We flag this at brief intake for every China-market project. Don’t find out at launch.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.